OpenEvidence, a Miami-based health tech startup, has made headlines with its recent announcement of raising $250 million in a Series D funding round, which has effectively doubled its valuation to an impressive $12 billion. This funding round marks a significant milestone for the company, being its fourth fundraising effort in less than a year, and brings the total capital raised since its inception in 2021 to nearly $700 million. The latest investment was co-led by Thrive Capital and Digital Sky Technologies (DST), with participation from notable investors such as GV (formerly Google Ventures), Sequoia Capital, Kleiner Perkins, and Coatue Management.
Founded by Daniel Nadler and Zachary Ziegler, OpenEvidence positions itself as a specialized AI-powered medical search engine designed to serve as a “brain extender” for clinicians. The platform aims to alleviate the overwhelming burden on healthcare professionals who struggle to keep up with the rapid pace of medical research and evolving clinical guidelines. By providing citation-linked answers from a vast array of medical literature, OpenEvidence empowers doctors to make informed decisions quickly and efficiently.
The significance of this funding round cannot be overstated, especially considering the current landscape of healthcare technology. As artificial intelligence continues to permeate various sectors, the healthcare industry is witnessing a surge in AI-related investments. In fact, Crunchbase data indicates that global funding for AI health tech companies reached an estimated $14 billion in 2025 alone, reflecting a remarkable 63% increase compared to the total amount raised in 2024. This trend underscores the growing recognition of AI’s potential to address high-cost and high-pain points within the healthcare system.
OpenEvidence’s platform has already demonstrated its efficacy, achieving $100 million in annual revenue as of January. The service is free for physicians, operating on an ad-supported model, which allows it to reach a broad audience without imposing financial barriers on healthcare providers. The platform’s user base is substantial, with over 40% of U.S. physicians reportedly utilizing OpenEvidence daily across more than 10,000 hospitals and medical centers. This widespread adoption highlights the critical role that OpenEvidence plays in the clinical workflow, particularly as it supported approximately 18 million clinical consultations in December alone—an impressive increase from just 3 million consultations per month a year prior.
The impact of OpenEvidence extends beyond mere numbers; it represents a paradigm shift in how healthcare professionals access and utilize medical information. In a world where a physician would need to dedicate nine hours each day to stay current with the latest findings from the top ten medical journals and specialty guidelines, OpenEvidence offers a solution that streamlines this process. As CEO Daniel Nadler aptly stated, “Without a technology like OpenEvidence, doctors may miss critical new findings or guidelines simply because they lack the time to find them.” This sentiment resonates deeply within the medical community, where time is often a luxury that practitioners cannot afford.
The timing of OpenEvidence’s funding round is particularly noteworthy, given the increasing interest from major players in the AI space, such as OpenAI and Anthropic, who are also venturing into healthcare offerings. These developments signal a broader trend toward integrating advanced technologies into clinical practice, aiming to enhance patient care and improve outcomes. OpenEvidence’s established presence in the market positions it favorably against these emerging competitors, as it has already embedded itself within the clinical workflows of numerous healthcare institutions.
Moreover, the startup’s commitment to supporting physicians in their quest for knowledge aligns with the overarching goal of improving patient care. In 2023, more than 100 million Americans received treatment from doctors utilizing OpenEvidence, showcasing the platform’s extensive reach and influence on healthcare delivery. As the demand for efficient and accurate medical information continues to grow, OpenEvidence is poised to play a pivotal role in shaping the future of healthcare.
The implications of OpenEvidence’s success extend beyond its immediate business achievements. The startup exemplifies the potential of AI to transform healthcare by addressing the challenges faced by clinicians in accessing relevant information. As the healthcare landscape evolves, the integration of AI-driven solutions like OpenEvidence will likely become increasingly essential in ensuring that healthcare providers can deliver high-quality care in a timely manner.
In conclusion, OpenEvidence’s recent funding achievement and its innovative approach to enhancing medical decision-making underscore the transformative power of AI in healthcare. As the company continues to expand its reach and refine its platform, it stands at the forefront of a movement that seeks to empower healthcare professionals and improve patient outcomes. With a robust investor backing and a clear vision for the future, OpenEvidence is well-positioned to lead the charge in revolutionizing how medical information is accessed and utilized in clinical practice. As the healthcare industry grapples with the complexities of modern medicine, solutions like OpenEvidence will be instrumental in bridging the gap between knowledge and practice, ultimately benefiting both providers and patients alike.